
Agata Juszczak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3225951/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of an exoglycosidase plate-based assay for detecting α1-3,4 fucosylation biomarker in individuals with HNF1A-MODY. Glycobiology, 2022, 32, 230-238.	1.3	3
2	Fucosylated AGP glycopeptides as biomarkers of HNF1A-Maturity onset diabetes of the young. Diabetes Research and Clinical Practice, 2022, 185, 109226.	1.1	4
3	Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods. Glycoconjugate Journal, 2021, 38, 375-386.	1.4	10
4	Response to Comment on Misra et al. Homozygous Hypomorphic HNF1A Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulfonylurea-Sensitive Diabetes. Diabetes Care 2020;43:909–912. Diabetes Care, 2020, 43, e155-e156.	4.3	0
5	Altered cortisol metabolism in individuals with HNF1Aâ€MODY. Clinical Endocrinology, 2020, 93, 269-279.	1.2	4
6	Homozygous Hypomorphic <i>HNF1A</i> Alleles Are a Novel Cause of Young-Onset Diabetes and Result in Sulfonylurea-Sensitive Diabetes. Diabetes Care, 2020, 43, 909-912.	4.3	13
7	Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult–Onset Nonautoimmune Diabetes. Diabetes Care, 2019, 42, 17-26.	4.3	44
8	Maturity onset diabetes of the young due to HNF1A variants in Croatia. Biochemia Medica, 2018, 28, 020703.	1.2	17
9	When to consider a diagnosis of MODY at the presentation of diabetes: aetiology matters for correct management. British Journal of General Practice, 2016, 66, e457-e459.	0.7	19
10	The management of Cushing's disease - from investigation to treatment. Endokrynologia Polska, 2013, 64, 166-74.	0.3	3
11	MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. European Journal of Endocrinology, 2012, 167, 1-5.	1.9	120